Background and activities



  • M.D. 1988
  • Ph.D. 1996
  • Specialist in clinical immunology and transfusion medicine

Current positions

  • Professor of cell biology and hematological cancer, NTNU
  • Senior Consultant, Dept. of Immunology and Transfusion Medicine, St. Olavs Hospital


Research highlights in the study of multiple myeloma (MM):

  • 1993: Description of a new separation method for MM cells based on antibodies against syndecan-1 (CD138).
  • 1994: Establishment of OH-2, an IL-6- and TNF-dependent MM cell line that has since been shown to be a unique hyperdiploid cell line without IgH translocations.
  • 1996: The first publication ever on NF-kappa-B activation in human MM cells
  • 1996: First publications on expression of hepatocyte growth factor (HGF) and autocrine stimulation of the HGF receptor c-Met in MM cells.
  • 1996: Elevation of HGF in serum from patients with MM compared to healthy controls
  • 1998: Serum HGF concentration is a prognostic factor for patients with MM and is reduced after response to treatment.
  • 1999: Description of a dual role of Fas in myeloma cells; induction of both apoptosis and proliferative responses.
  • 1999: HGF induces production of the osteoclast-stimulating cytokine IL-11 in osteoblastic cells.
  • 1999: First paper showing proliferation of myeloma cells induced by IL-15 and production of IL-15 mRNA in MM cells.
  • 1999: Establishment of a mouse model for MM showing depletion of osteoblasts from affected skeletal tissue.
  • 2000: First paper on prognostic impact of serum level of syndecan-1 in patients with MM
  • 2000: Polarization of syndecan-1 and heparin-binding molecules on the surface of MM cells
  • 2000: High levels of syndecan-1 in MM bone marrow modulate the activity of HGF.
  • 2000: First paper on expression of urokinase plasminogen activator (uPA) and the aPA receptor in MM cells.
  • 2001: Bone morphogenetic protein-4 (BMP-4) induces apoptosis in MM cells.
  • 2001: First paper showing reduced levels of osteoprotegerin (OPG) in serum from patients with MM
  • 2002: First paper on proliferative effect of IL-21 on MM cells.
  • 2002: Serum IGF-1 is not elevated in MM patients, but is still a prognostic factor
  • 2002: OPG is bound and internalized by MM cells.
  • 2004: BMP-5, -6 and -7 induce apoptosis in MM cells.
  • 2004: Osteopontin is an adhesive factor for MM cells and is increased in serum from patients with MM
  • 2005: An inhibitor of HGF receptor c-Met blocks autocrine growth of MM cells.
  • 2005: HGF induces adhesion of MM cells to fibronectin
  • 2006: First paper showing that toll-like receptors mediate proliferation of MM cells.
  • 2007: HGF inhibits BMP-induced osteoclastogensis.
  • 2008: Metastasis-associated phosphatase PRL-3 is expressed in malignant but not in healthy plasma cells.
  • 2008: HGF promotes migration of MM cells
  • 2008: Elevated serum levels of HGF activator in patients with MM
  • 2010: Myeloma cell line OH-2 is hyperdiploid and represents a subgroup of myeloma cases that are frequent but rarely give rise to cell lines.
  • 2011: The kinase SGK-1 is expressed in myeloma cells where it promotes cell growth.
  • 2012: BMPs induce apoptosis of myeloma cells by repressing MYC.
  • 2013: Anti-c-Met nanobodies as potential myeloma drug.
  • 2013: Synergy between HGF, IGF-1 and SGK-1 in promoting myeloma cell growth.
  • 2016: PRL-3 is important for IL-6-mediated survival of myeloma cells.
  • 2017: Src Family Kinases Are Regulated in Multiple Myeloma Cells by PRL-3
  • 2017: First papers showing that PRL-3 is overexpressed in prostate cancer cells and is associated with an unfavorable prognosis
  • 2018: PRL-3 is expressed and is important for migration in B cell lymphoblastic leukemia and Hodgkin lymphoma
  • 2020: Myeloma converts ATP to immunosuppressive adenosine by the enzymes CD39 and CD73. Immunosuppression can be reverted by blocking CD39 and adenosine receptors. 
  • 2021: Inhibitors of PHGDH, an enzyme in the serine synthesis pathway, can induce death of myeloma cells both in vitro and in vivo.
  • 2021: PRL-3 stimulates aerobic glycolysis in myeloma cells.
  • 2021: PRL-3 acts primarily as a pseudophosphatase.

Scientific, academic and artistic work

Displaying a selection of activities. See all publications in the database

Journal publications